Benzinga | Oct 20, 2021 10:18AM EDT

Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $84

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and lowers the price target from $100 to $84.